426 related articles for article (PubMed ID: 8341998)
1. [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].
Brändli O; Dreher D; Morger D
Schweiz Med Wochenschr; 1993 Jun; 123(25):1300-6. PubMed ID: 8341998
[TBL] [Abstract][Full Text] [Related]
2. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
[TBL] [Abstract][Full Text] [Related]
3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
4. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
[TBL] [Abstract][Full Text] [Related]
5. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
Teo SK
Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
[TBL] [Abstract][Full Text] [Related]
6. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
Su WJ; Perng RP
Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
[TBL] [Abstract][Full Text] [Related]
7. Fixed dose combination short course chemotherapy in the treatment of pulmonary tuberculosis.
Wolde K; Lema E; Roscigno G; Abdi A
Ethiop Med J; 1992 Apr; 30(2):63-8. PubMed ID: 1345030
[TBL] [Abstract][Full Text] [Related]
8. [Controlled study comparing 3 daily chemotherapy regimens for six months in pulmonary tuberculosis in routine practice in Algiers. Results at 30 months].
Mazouni L; Tazir M; Boulahbal F; Chaulet P
Rev Mal Respir; 1985; 2(4):209-14. PubMed ID: 3937189
[TBL] [Abstract][Full Text] [Related]
9. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
[TBL] [Abstract][Full Text] [Related]
10. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
[TBL] [Abstract][Full Text] [Related]
11. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of 3 6-month chemotherapy regimes in pulmonary tuberculosis in routine practice in Algiers. 18th-month results].
Chaulet P; Boulahbal F; Ait Khaled N; El Awadi Z; Tazir M
Rev Fr Mal Respir; 1983; 11(5):667-76. PubMed ID: 6658153
[TBL] [Abstract][Full Text] [Related]
13. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
[TBL] [Abstract][Full Text] [Related]
14. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
16. Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
Snider DE; Zierski M; Graczyk J; Bek E; Farer LS
Eur J Respir Dis; 1986 Jan; 68(1):12-8. PubMed ID: 3512281
[TBL] [Abstract][Full Text] [Related]
17. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W
Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263
[TBL] [Abstract][Full Text] [Related]
18. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
Small PM; Schecter GF; Goodman PC; Sande MA; Chaisson RE; Hopewell PC
N Engl J Med; 1991 Jan; 324(5):289-94. PubMed ID: 1898769
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis.
Bartacek A; Schütt D; Panosch B; Borek M;
Int J Tuberc Lung Dis; 2009 Jun; 13(6):760-6. PubMed ID: 19460254
[TBL] [Abstract][Full Text] [Related]
20. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
